ANTICANCER FUSION PROTEIN
A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an i...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | PIECZYKOLAN, JERZY SZCZEPAN PAWLAK, SEBASTIAN LEMKE, KRZYSZTOF KAZIMIERZ ZEREK, BARTLOMIEJ |
| description | A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a).The fusion protein can be used for the treatment of cancer diseases.
L'invention concerne un domaine (a) comprenant une protéine de fusion qui est un fragment fonctionnel de la séquence protéique hTRAIL, dont le fragment commence par un acide aminé à une position non inférieure à hTRAIL95, ou un homologue dudit fragment fonctionnel ayant au moins une identité de séquence de 70%; et un domaine (b) qui est une séquence d'un peptide effecteur immunostimulant, la séquence du domaine (b) étant fixée à l'extrémité C-terminale ou N-terminale du domaine (a). La protéine de fusion peut être utilisée pour le traitement de maladies cancéreuses. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA2814595C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA2814595C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA2814595C3</originalsourceid><addsrcrecordid>eNrjZJB09AvxdHb0c3YNUnALDfb091MICPIPcfX042FgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORhaGJqaWps7GhFUAAJ_jHzc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANTICANCER FUSION PROTEIN</title><source>esp@cenet</source><creator>PIECZYKOLAN, JERZY SZCZEPAN ; PAWLAK, SEBASTIAN ; LEMKE, KRZYSZTOF KAZIMIERZ ; ZEREK, BARTLOMIEJ</creator><creatorcontrib>PIECZYKOLAN, JERZY SZCZEPAN ; PAWLAK, SEBASTIAN ; LEMKE, KRZYSZTOF KAZIMIERZ ; ZEREK, BARTLOMIEJ</creatorcontrib><description>A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a).The fusion protein can be used for the treatment of cancer diseases.
L'invention concerne un domaine (a) comprenant une protéine de fusion qui est un fragment fonctionnel de la séquence protéique hTRAIL, dont le fragment commence par un acide aminé à une position non inférieure à hTRAIL95, ou un homologue dudit fragment fonctionnel ayant au moins une identité de séquence de 70%; et un domaine (b) qui est une séquence d'un peptide effecteur immunostimulant, la séquence du domaine (b) étant fixée à l'extrémité C-terminale ou N-terminale du domaine (a). La protéine de fusion peut être utilisée pour le traitement de maladies cancéreuses.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200616&DB=EPODOC&CC=CA&NR=2814595C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200616&DB=EPODOC&CC=CA&NR=2814595C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PIECZYKOLAN, JERZY SZCZEPAN</creatorcontrib><creatorcontrib>PAWLAK, SEBASTIAN</creatorcontrib><creatorcontrib>LEMKE, KRZYSZTOF KAZIMIERZ</creatorcontrib><creatorcontrib>ZEREK, BARTLOMIEJ</creatorcontrib><title>ANTICANCER FUSION PROTEIN</title><description>A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a).The fusion protein can be used for the treatment of cancer diseases.
L'invention concerne un domaine (a) comprenant une protéine de fusion qui est un fragment fonctionnel de la séquence protéique hTRAIL, dont le fragment commence par un acide aminé à une position non inférieure à hTRAIL95, ou un homologue dudit fragment fonctionnel ayant au moins une identité de séquence de 70%; et un domaine (b) qui est une séquence d'un peptide effecteur immunostimulant, la séquence du domaine (b) étant fixée à l'extrémité C-terminale ou N-terminale du domaine (a). La protéine de fusion peut être utilisée pour le traitement de maladies cancéreuses.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB09AvxdHb0c3YNUnALDfb091MICPIPcfX042FgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORhaGJqaWps7GhFUAAJ_jHzc</recordid><startdate>20200616</startdate><enddate>20200616</enddate><creator>PIECZYKOLAN, JERZY SZCZEPAN</creator><creator>PAWLAK, SEBASTIAN</creator><creator>LEMKE, KRZYSZTOF KAZIMIERZ</creator><creator>ZEREK, BARTLOMIEJ</creator><scope>EVB</scope></search><sort><creationdate>20200616</creationdate><title>ANTICANCER FUSION PROTEIN</title><author>PIECZYKOLAN, JERZY SZCZEPAN ; PAWLAK, SEBASTIAN ; LEMKE, KRZYSZTOF KAZIMIERZ ; ZEREK, BARTLOMIEJ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA2814595C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2020</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>PIECZYKOLAN, JERZY SZCZEPAN</creatorcontrib><creatorcontrib>PAWLAK, SEBASTIAN</creatorcontrib><creatorcontrib>LEMKE, KRZYSZTOF KAZIMIERZ</creatorcontrib><creatorcontrib>ZEREK, BARTLOMIEJ</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PIECZYKOLAN, JERZY SZCZEPAN</au><au>PAWLAK, SEBASTIAN</au><au>LEMKE, KRZYSZTOF KAZIMIERZ</au><au>ZEREK, BARTLOMIEJ</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANTICANCER FUSION PROTEIN</title><date>2020-06-16</date><risdate>2020</risdate><abstract>A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a).The fusion protein can be used for the treatment of cancer diseases.
L'invention concerne un domaine (a) comprenant une protéine de fusion qui est un fragment fonctionnel de la séquence protéique hTRAIL, dont le fragment commence par un acide aminé à une position non inférieure à hTRAIL95, ou un homologue dudit fragment fonctionnel ayant au moins une identité de séquence de 70%; et un domaine (b) qui est une séquence d'un peptide effecteur immunostimulant, la séquence du domaine (b) étant fixée à l'extrémité C-terminale ou N-terminale du domaine (a). La protéine de fusion peut être utilisée pour le traitement de maladies cancéreuses.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA2814595C |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | ANTICANCER FUSION PROTEIN |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T21%3A51%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PIECZYKOLAN,%20JERZY%20SZCZEPAN&rft.date=2020-06-16&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA2814595C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |